β_2mG McAb RIA法研究EPO对CRF患者肾功能的影响

Study of Effects of rHuEPO on Renal Function in Patients with CRF Using β_2mG-McAb-RIA

β2微球蛋白(β2mG)已作为检测肾脏功能的灵敏指标应用于临床。重组人红细胞生长素(rHuEPO)是治疗慢性肾功能衰竭(CRF)的药物。本文采用β2mG-McAb宽检测范围(0.31～10μg/ml)的RIA,观察15例CRF患者用rHuEPO治疗后,对贫血和肾功能的影响。结果表明:治疗后,患者Hb明显升高(P<0.01),但血清β2mG与治疗前(25.52±1.76μg/ml)无明显差异。提示rHuEPO对于肾脏功能没有改善和恶化作用,而有改善贫血的效果。

β_2 microglobulin (β_2 mG) is a globulin with small molecular weight. Its determination has played an important role in assaying of renal function. The effect of recombinant human erythropoietin (rHuEPO) as an agent on renal function in 15 patients with chronic renal failure (CRF) was evaluated by β_2 mG-McAb-RIA with wide range (0.31~10.0μg/ml) .The results indicate that hemo-globin (Hb) is significantly higher (P<0.01) after treatment. However there is not markedly difference of serum β_2 mG levels (25.52±1.76μg/ml) and after using rHuEPO. It is indicated that rHuEPO can increase Hb levels, but it might not improve renal functions of CRF patients.